8 Stocks Wall Street Analysts Love Most

Dear , There's no such thing as a free lunch on Wall Street.  But I believe I've found something pretty darn close.  And I'll be releasing a brand new Sniper Report about this explosive time-sensitive opportunity.     When a company sets to acquire another firm in the public market, typically the acquired company will jump to the merger deal price, and trade at that level until it finally closes.  For example, check out this chart of Craft Brew Alliance (BREW), a company that will be acquired by Anheuser-Busch for $16.50 per share.  BREW is trading right near its deal price of $16.50 During the COVID-19 panic sell-off, BREW plummeted to $10.71, creating an incredible opportunity to buy a stock that will close at $16.50 when the deal is finalized.  With the stock now trading at $15.84, the easy money in this trade has vanished.  So why am I bringing this up? Simple.  I just discovered another merger and acquisition play.  Except this stock hasn't recovered back to its proposed deal price.  In fact, it's trading at about a 50% discount.  And like the previous example, this stock is set to be acquired by a well-established company in the automobile industry—Volkswagen.  There are some major players involved in the deal, including billionaire investor, Carl Icahn. I'm ready to pull the trigger on this stock any day now.  I'll be issuing a brand new Sniper Report detailing my thesis behind the play, as well as an alert when I enter this position.  My only fear is that Volkswagen announces the deal and I'm not in.  And with the market running as hot as it has been—it could happen at any moment.  To ensure you get my special alert you must be subscribed to my Sniper Report service. It's extremely rare to find a quality stock trading a steep discount—which is set to be acquired. But that's exactly the opportunity we have in front of us right now.   It almost feels like there's free money on the table—waiting for someone to take it.  When you join Sniper Report you'll not only receive this special alert, but you'll also gain access to 12-months of my highest conviction investment ideas.  But you must hurry, the market waits for no one.  Get instant access to my alert as soon as it drops.  This is just too good to pass up. Kyle Dennis RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 Click Here to stop receiving emails from kyle@biotechbreakouts.com Unsubscribe from all RagingBull emails Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative's own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.